Mehdi Hamadani

Mehdi Hamadani

Medical College of Wisconsin - Milwaukee / United States
Others
AD Scientific Index ID: 1389277
person_outline Mehdi Hamadani's MOST POPULAR ARTICLES
1-) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromesBL Scott, MC Pasquini, BR Logan, J Wu, SM Devine, DL Porter, ...Journal of Clinical Oncology 35 (11), 1154, 20174752017
2-) Current use of and trends in hematopoietic cell transplantation in the United StatesA D\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Souza, C Fretham, SJ Lee, M Arora, J Brunner, S Chhabra, S Devine, ...Biology of Blood and Marrow Transplantation 26 (8), e177-e182, 20203172020
3-) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trialNN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ...Nature medicine 26 (10), 1569-1575, 20203172020
4-) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trialPF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ...The Lancet Oncology 22 (6), 790-800, 20213862021
5-) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual diseaseCS Hourigan, LW Dillon, G Gui, BR Logan, M Fei, J Ghannam, Y Li, ...Journal of Clinical Oncology 38 (12), 1273-1283, 20203652020